© Reuters.
STOCKHOLM – Calliditas Therapeutics AB (NASDAQ: CALT) (STO: CALTX), a biopharmaceutical company specializing in rare diseases, announced significant growth in its fourth-quarter revenue, with preliminary net revenue for its product TARPEYO between $31 million and $33 million. This represents a substantial increase from the third quarter. The company also reported preliminary net TARPEYO revenues for the full year of 2023, amounting to $100 million to $102 million, which is over a 170% increase from 2022.
The total revenues for 2023 are expected to reach between $110 million and $113 million, aided by milestone payments and royalty income from the Nefecon franchise outside the United States. The fourth quarter also marked a record in patient enrollments, with 555 new TARPEYO prescriptions.
These preliminary results reflect estimates based on currently available information and are subject to change following the completion of financial closing procedures.
Calliditas CEO Renée Aguiar-Lucander credited the full approval of TARPEYO in the U.S., enhanced product protection, and record fourth-quarter enrollments as key factors contributing to the company’s strong position for driving growth and profitability in 2024.
The information provided is based on a press release statement and reflects Calliditas’ expectations as of today.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
